Complications and Adverse Sequelae of Leg Vein Sclerotherapy

Complications in Dermatologic Surgery

Volumn , Issue , 2008, Pages 219-242

  Goldman, Mitchel P ^a   Sadick, Neil S ^b  

^a Cornell University Medical College ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84908287480     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04546-9.10014-7     Document Type: Chapter

References (155)

1. M.P. Goldman, J.B. Bergan and J.J. Guex (Eds) (2006) Sclerotherapy treatment of varicose and telangiectatic leg veins 4th edn New York: Mosby-Elsevier
2. M.P. Goldman (2002) Treatment of varicose and telangiectatic leg veins: double blind prospective comparative trial between Aethoxysklerol and Sotradecol. Dermatol Surg 28 52-55.
3. R. Weiss and M. Weiss (1990) Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy. J Dermatol Surg Oncol 16 333-336.
4. D.M. Duffy (1988) Small vessel sclerotherapy: an overview. J.P. Callen (Eds) Advances in dermatology, Vol 3 Chicago: Mosby
5. S.W. White and C. Besanceney (1983) Systemic pigmentation from tetracycline and minocycline therapy. Arch Dermatol 119 1-2.
6. J. Gawrychowski, B. Lazar-Czyzewska and A. Romanski (1995) A comparative study of three sclerosing agents in the treatment of telangiectasias. Phlebology '95 1(Suppl), 530.
7. M. Izzo, F. Mariani, F. Binaghi, et al. (1995) Postsclerotherapy hyperpigmentation: incidence, clinical features, and therapy. Phlebology '95 1(Suppl), 550.
8. P. Santoro, M. Blandamura, D. Chiti, et al. (2001) Postsclerotherapy occurrence of hyperpigmentation and other local and systemical signs in the treatment of small vessel varices with different sclerotherapic agents. Acta Phlebol 2 43-49.
9. H.I. Biegeleisen and R.M. Biegeleisen (1976) The current status of sclerotherapy for varicose veins. Clin Med 83 24.
10. B.B. Chrisman (1982) Treatment of venous ectasias with hypertonic saline. Hawaii Med J 41 406.
11. H. Chatard (1976) Discussion de la question de JC Allart: pigmentations post-sclerotherapiques. Phlébologie 29 211-216.
12. M.P. Goldman, R.P. Kaplan, L.N. Oki, et al. (1987) Sclerosing agents in the treatment of telangiectasia: comparison of the clinical and histologic effects of intravascular polidocanol, sodium tetradecyl sulfate, and hypertonic saline in the dorsal rabbit ear vein model. Arch Dermatol 123 1196-1201.
13. M. Bessis (1973) Living blood cells and their ultrastructure. Berlin: Springer-Verlag
14. M. Bessis, L.S. Lessin and E. Beutler (1983) Morphology of the erythron. W.J. Williams (Eds) Hematology 3rd edn New York: McGraw-Hill
15. H. Chatarel and H. Dufour (1983) Note sur la nature mixtre, hématique et mélanique, des pigmentations en phlébologie. Phlébologie 36 303-306.
16. N. Klüken and M. Zabel (1983) La pigmentation est-elle un signe caractéristique de l'insuffisance veineuse chronique? Phlébologie 36 315.
17. B.A. Gilchrest, J.S. Stoff and N.A. Soter (1982) Chronologic aging alters the response to ultraviolet-induced inflammation in human skin. J Invest Dermatol 79 11-15.
18. W.D. Jacoby (1991) Comment 21. Schoch Lett 41 2.
19. D.J. Leffell (1991) Minocycline hydrochloride hyperpigmentation complicating treatment of venous ectasia of the extremities. J Am Acad Dermatol 24 501-502.
20. C.M. Dwyer, A.M. Cuddihy, R.E. Kerr, et al. (1993) Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol 129 158-162.
21. N.A. Fenske, J.L. Millns and K.E. Greer (1980) Minocycline-induced pigmentation at sites of cutaneous inflammation. JAMA 244 1103-1106.
22. D.J. Eedy and D. Burrows (1991) Minocycline-induced pigmentation occurring in two sisters. Clin Exp Dermatol 16 55-57.
23. R.S.W. Basler and P.W. Kohnen (1978) Localized hemosiderosis as a sequela of acne. Arch Dermatol 114 1695-1697.
24. R.S.W. Basler (1979) Minocycline therapy for acne (letter). Arch Dermatol 115 1391.
25. H.A. Ridgway, T.S. Sonnex, C.T. Kennedy, et al. (1982) Hyperpigmentation associated with oral minocycline. Br J Dermatol 107 95-102.
26. S. Sato, G.F. Murphy, J.D. Bernhard, et al. (1981) Ultrastructural and x-ray microanalytical observations of minocycline-related hyperpigmentation of the skin. J Invest Dermatol 77 264-271.
27. G. Gordon, B.M. Sparano and M.J. Iatropoulos (1985) Hyperpigmentation of the skin associated with minocycline therapy. Arch Dermatol 121 618-623.
28. N. Okada, K. Moriya, K. Nishida, et al. (1989) Skin pigmentation associated with minocycline therapy. Br J Dermatol 121 247-254.
29. L. Wenner (1981) Sind endovarikose hamatische ansammlungen eine normalerscheinung bei sklerotherapie? Vasa 10 174-176.
30. H.J. Leu, A. Wenner and M.A. Spycher (1981) Erythrocyte diapedesis in venous stasis syndrome. Vasa 10 17-23.
31. E.J. Orbach (1979) Hazards of sclerotherapy of varicose veins – their prevention and treatment of complications. Vasa 8 170-173.
32. A.H. Scultetus, J.L. Villavicencio, T.C. Kao, et al. (2003) Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg 38 896-903.
33. R.A. Weiss, N.S. Sadick, M.P. Goldman, et al. (1999) Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg 25 105-108.
34. Shoden A, Sturgeon P. Hemosiderin. I. A physicochemical study. Acta Haematol (Basel) 1960; 23:376.
35. C.I. Wells and J.J. Wolken (1962) Biochemistry: microspectrophotometry of haemosiderin granules. Nature 193 977-978.
36. A. Tafazzoli, E.F. Rostan and M.P. Goldman (2000) Q-switched ruby laser treatment for postsclerotherapy hyperpigmentation. Dermatol Surg 26 653-656.
37. R.A. Weiss and M.A. Weiss (2004) Treatment of severe post-sclerotherapy hyperpigmentation with Q-switched ruby laser. Lasers Med Surg 16 55.
38. K.L. Beasley, R.A. Weiss, M.A. Weiss, et al. (2004) Treatment of post-sclerotherapy hyperpigmentation with a novel Q-switched combination 532/1064 nm Nd:YAG laser. Lasers Med Surg 16 15.
39. J.L. Shields and G.T. Jansen (1982) Therapy for superficial telangiectasias of the lower extremities. J Dermatol Surg Oncol 8 857-860.
40. M.P. Goldman, D. Beaudoing, W. Marley, et al. (1990) Compression in the treatment of leg telangiectasia. J Dermatol Surg Oncol 16 322-325.
41. R.A. Weiss and M.A. Weiss (1990) Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs polidocanol. J Dermatol Surg Oncol 16 800-804.
42. K. Strehlow, N. Werner, J. Berweiller, et al. (2003) Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 3059-3065.
43. L.T. Davis and D.M. Duffy (1990) Determination of incidence and risk factors for post-sclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol 16 327-330.
44. J. Denekamp (1993) Angiogenesis, neovascular proliferation, and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66 181-196.
45. E.R. Clark and E.L. Clark (1932) Observations on living preformed blood vessels as seen in a transparent chamber inserted into the rabbit's ear. Am J Anat 49 441.
46. E.R. Clark and E.L. Clark (1940) Microscopic observations on the extracellular cells of living mammalian blood vessels. Am J Anat 66 1.
47. N.S. Sadick (2003) The role of hormones in the treatment of spider telangiectasia of the lower extremities: effects on efficacy and posttreatment complications. J Cosmet Dermatol 16 44-46.
48. M. Schiff and H.F. Burn (1961) The effect of intravenous estrogens on ground substance. Arch Otolaryngol 73 43.
49. A. Gagliardi and D.C. Collins (1993) Inhibition of angiogenesis by antiestrogens. Cancer Res 53 533-535.
50. E.F. Haran, A.F. Maretzek, I. Goldberg, et al. (1994) Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelial growth. Cancer Res 54 5511-5514.
51. K. Strehlow, N. Werner, J. Berweiller, et al. (2003) Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 3059-3065.
52. G.H. Saski, C.Y. Pang and J.L. Wittcliff (1984) Pathogenesis and treatment of infant skin strawberry hemangiomas: clinical and in vitro studies of normal effects. Plast Reconstr Surg 73 359-370.
53. M.L. Puisseau-Lupo (1989) Sclerotherapy – a review of results and complications in 200 patients. J Dermatol Surg Oncol 15 214-219.
54. M.P. Goldman and R.E. Fitzpatrick (1990) Pulsed-dye laser treatment of leg telangiectasia with and without simultaneous sclerotherapy. J Dermatol Surg Oncol 16 338-344.
55. M.P. Goldman and S. Eckhouse (1996) Photothermal sclerosis of leg veins. Dermatol Surg 22 323-330.
56. M.P. Goldman (1998) Treatment of benign vascular lesions with the Photoderm VL high-intensity pulsed light source. Adv Dermatol 13 503.
57. R.M. Adrian (1998) Treatment of leg telangiectasias using a long-pulse frequency-doubled neodymium:YAG laser at 532 nm. Dermatol Surg 24 19-23.
58. B. Perez, M. Nunez, P. Boixeda, et al. (1997) Progressive ascending telangiectasia treated with the 585 nm flashlamp-pumped pulsed dye laser. Lasers Surg Med 21 413-416.
59. J. Upton, J.B. Mulliken and J.E. Murray (1979) Major extravasation injuries. Am J Surg 137 489.
60. P. Yosowitz, D.A. Ekland, R.C. Shaw, et al. (1975) Peripheral intravenous infiltration necrosis. Ann Surg 182 553-556.
61. W. Eaglstein (1990) Inadvertent intracutaneous injection with hypertonic saline (23.4%) in two patients without complications. J Dermatol Surg Oncol 16 878-879.
62. D.M. Duffy (1993) Setting up a vein treatment center: incorporating sclerotherapy into the dermatologic practice. Semin Dermatol 12 150-158.
63. D.M. Duffy (1999) Cutaneous necrosis following sclerotherapy. J Aesthet Dermatol Cosmet Surg 1 157.
64. J.J. Jaquier and R.M. Loretan (1969) Clinical trials of a new sclerosing agent, aethoxysklerol. Soc Fr Phlebol 22 383.
65. J.L. De Faria and I.N. Moraes (1963) Histopathology of the telangiectasias associated with varicose veins. Dermatologica 127 321.
66. I. Bihari and E. Magyar (1999) Microshunt histology in telangiectasias. Int J Angiol 8 98.
67. I. Bihari and E. Magyar (2001) Reasons for ulceration after injection treatment of telangiectasia. Dermatol Surg 27 133-136.
68. Conrad P, Malouf GM. The Australian Polidocanol (Aethoxysklerol) Open Clinical Trial results at two years. Presented at the Annual Meeting of the North American Society of Phlebology. Maui, Hawaii, Feb 21, 1984.
69. G. Bassi (1978) R. Santler, H. Lindemayer, A. Bolliger (Eds) Grenzen und Gefahren in der Phlebologie und Proktologie (Tischgesprach 1) Stuttgart: Schattauer
70. W. Leun and B.H. Langmaack (1955) Die Grenzen und Gefahren der Varizenverodung. Dtsch Med Wochenschr 80 257-260.
71. P. Buri and U. Brunner (1980) Die versehentliche Injektion von Verodungsmitteln in die Arteria tibialis posterior. U. Brunner (Eds) Die Knoechelregion. Aktulle Probleme in der Angiologie Bern: Huber
72. J.A. Dinkler and B.E. Cohen (1989) Reversal of dopamine extravasation injury with topical nitroglycerin ointment. J Plast Reconstr Surg 84 811.
73. AMA drug evaluation. 6th edn Chicago: American Medical Association
74. A.G. Franks (1982) Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 1 76-77.
75. M. Ross (1991) Dopamine-induced localized cutaneous vasoconstriction and piloerection. Arch Dermatol 127 586-587.
76. J. Guckens, E. Rabe and T. Bieber (1999) Embolia cutis medicamendosa of the foot after sclerotherapy. Eur J Dermatol 9 132-133.
77. N.S. Sadick (2000) Postsclerotherapy ulcerations secondary to a hypercoagulable state. Cosmet Dermatol 13 18.
78. M.P. James and H. Grech (2002) Subclinical, primary antiphospholipid syndrome unmasked by sclerotherapy. Br J Dermatol 146 527-528.
79. S.E. Zimmet (1993) The prevention of cutaneous necrosis following extravasation of hypertonic saline and sodium tetradecyl sulfate. J Dermatol Surg Oncol 19 641-646.
80. K.E. Senk (1981) Management of intravenous extravasation. Infusion 5 77.
81. R.T. Dorr and D.S. Alberts (1985) Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74 113-120.
82. S.W. Laurie, K.L. Wilson, D.A. Kernahan, et al. (1984) Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. Ann Plast Surg 13 191-194.
83. K.E. Zenk, C.L. Dungy and G.R. Greene (1981) Nafcillin extravasation injury: use of hyaluronidase as an antidote. Am J Dis Child 135 1113-1114.
84. W.V. Razka Jr., T.K. Kueser, F.R. Smith, et al. (1990) The use of hyaluronidase in the treatment of intravenous extravasation injuries. J Perinatol 10 146-149.
85. R.T. Dorr and D.S. Alberts (1981) Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. Cancer Treat Rep 65 1001-1006.
86. A.S. Brown, D.J. Hoelzer and S.A. Piercy (1979) Skin necrosis from extravasation of intravenous fluids in children. Plast Reconstr Surg 64 145-150.
87. G.N. Beall, R. Casaburi and A. Singer (1986) Anaphylaxis – everyone's problem (specialty conference). West J Med 144 329-337.
88. S.I. Wasserman (1983) Anaphylaxis. E. Middleton, C.E. Reed, E.F. Ellis (Eds) Allergy: principles and practice 2nd edn St Louis: Mosby
89. J. Shelley (1939) Allergic manifestations with injection treatment of varicose veins: death following injection of monoethanolamine oleate. JAMA 112 1792.
90. A.A. Schmier (1937) Clinical comparison of sclerosing solutions in injection treatment of varicose veins. Am J Surg 36 389.
91. L.M. Zimmerman (1934) Allergic-like reactions from sodium morrhuate in obliteration of varicose veins. JAMA 102 1216.
92. N.E. Meyer (1938) Monoethanolamine oleate: a new chemical for obliteration of varicose veins. Am J Surg 40 628.
93. K.M. Lewis (1936) Anaphylaxis due to sodium morrhuate. JAMA 107 1298.
94. E.T. Dick (1966) The treatment of varicose veins. N Z Med J 65 310-313.
95. S.K. Sarin and A. Kumar (1990) Sclerosants for variceal sclerotherapy: a critical appraisal. Am J Gastroenterol 85 641-649.
96. P. Monroe, C.F. Morrow, J.E. Millen, et al. (1983) Acute respiratory failure after sodium morrhuate esophageal sclerotherapy. Gastroenterology 85 693-699.
97. M.L. Dale (1937) Reaction due to injection of sodium morrhuate. JAMA 108 718.
98. A. Ritchie (1933) The treatment of varicose veins during pregnancy. Edinburgh Med J 40 157.
99. J.G. Probstein (1936) Major complications of intravenous therapy of varicose veins. J Missouri Med Assoc 33 349.
100. H. Dodd and J.B. Oldham (1940) Surgical treatment of varicose veins. Lancet 1 8.
101. A.A. De Lorimier (1995) Sclerotherapy for venous malformations. J Pediatr Surg 30 188-194.
102. H.I. Biegeleisen (1937) Fatty acid solutions for the injection treatment of varicose veins: evaluation of four new solutions. Ann Surg 105 610.
103. S.E. Hedberg, D.L. Fowler and L.R. Ryan (1982) Injection sclerotherapy of esophageal varices using ethanolamine oleate: a pilot study. Am J Surg 143 426-431.
104. R.R. Foote (1942) Severe reaction to monoethanolamine oleate. Lancet 1 390.
105. R.G. Reid and N.G. Rothine (1968) Treatment of varicose veins by compression sclerotherapy. Br J Surg 55 889-895.
106. M.P. Goldman and R.G. Bennett (1987) Treatment of telangiectasia: a review. J Am Acad Dermatol 17 167-182.
107. M.H. Steinberg (1955) Evaluation of sotradecol in sclerotherapy of varicose veins. Angiology 6 519-532.
108. R.A. Nabatoff (1950) Recent trends in the diagnosis and treatment of varicose veins. Surg Gynecol Obstet 90 521.
109. G. Fegan (1967) Varicose veins: compression sclerotherapy. London: Heinemann Medical
110. D.B. Alderman (1975) Surgery and sclerotherapy in the treatment of varicose veins. Conn Med 39 467-471.
111. P. Wallois (1971) Incidents et accidents au cours du traitement sclerosant des varices et leur prevention. Phlébologie 24 217-224.
112. L. Mantse (1985) A mild sclerosing agent for telangiectasias. J Dermatol Surg Oncol 11 855.
113. L. Mantse (1986) The treatment of varicose veins with compression sclerotherapy: technique, contraindications, complications. Am J Cosmet Surg 3 47.
114. Clinical Case 1. Presented at the Third Annual Meeting of the North American Society of Phlebology. Phoenix, Arizona, Feb 21, 1990.
115. S.J. Mubarak, C.A. Owen, A.R. Hargens, et al. (1978) Acute compartment syndromes: diagnosis and treatment with the aid of the wick catheter. J Bone Joint Surg Am 60 1091-1095.
116. H. Passas (1972) One case of tetradecyl-sodium sulfate allergy with general symptoms. Soc Fr Phlebol 25 19.
117. P.K. Thibault (1999) Sclerotherapy of varicose veins and telangiectasias: a 2-year experience with sodium tetradecyl sulphate. Aust N Z J Phlebol 3 25.
118. J.J. Guex, F.A. Allaert, J.L. Gillet, et al. (2005) Immediate and midterm complications of sclerotherapy: Report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 31 123-128.
119. Clin-Alert correspondence #263; 1992.
120. L. Reiner (1946) The activity of anionic surface active compounds in producing vascular obliteration. Proc Soc Exp Biol Med 62 49.
121. M.P. Goldman (2004) Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe? Dermatol Surg 30 1454-1456.
122. A.E. Hoffer (1972) Aethoxysklerol (Kreussler) in the treatment of varices. Minerva Cardioang 20 601-604.
123. H. Fronek, A. Fronek and G. Saltzbarg (1989) Allergic reactions to Sotradecol. J Dermatol Surg Oncol 15 684.
124. H. Eichenberger (1969) Results of phlebosclerosation with hydroxypolyethoxydodecane. Zentralbl Phlebol 8 181-183.
125. B.H. Jacobesen (1974) Aethoxysklerol: a new sclerosing agent for varicose veins. Ugeskr Laeger 136 532-534.
126. W. Feuerstein (1973) Anaphylactic reaction to hydroxypolyaethoxydodecon. Vasa 2 292-294.
127. J.J. Guex (1993) Indications for the sclerosing agent polidocanol. J Dermatol Surg Oncol 19 959-961.
128. B.H. Stricker, J.A. van Oijen, C. Kroon, et al. (1990) Anafylaxie na gebruik van polidocanol. Ned Tijdschr Geneeskd 134 240-242.
129. P. Conrad, G.M. Malouf and M.C. Stacey (1995) The Australian polidocanol (Aethoxysklerol) study: results at 2 years. Dermatol Surg 21 334-336.
130. G. Lombari (1992) Sclerotherapy of varices: complications and their treatment. P. Raymond-Martimbeau, R. Prescott, M. Zummo (Eds) Phlébologie '92 Paris: John Libbey Eurotext
131. C.F. Fied, J.J. Jackson, T.S. Bren, et al. (1994) Allergic reactions to polidocanol for vein sclerosis: two case reports. J Dermatol Surg Oncol 20 466-468.
132. K.J. Siems and K. Soehring (1952) Die Ausschaltug sensibler nerven duren peridurale und paravertebrale injektion von alkylpolyathylenoxydathern bei meerschweinchen. Arzneimittelforschung 2 109-111.
133. K. Soehring (1951) Beitrage zur pharmakologie der alkylpolyathylenoxyd-derivate. I. Untersuchungen uber die acute und subchronische toxizitat bei verschiedenen tierarten. Arch Int Pharmacodyn Ther 87 301-320.
134. K. Soehring and M. Frahm (1955) Studies on the pharmacology of alkylpolyethyleneoxide derivatives. Arzneimittelforschung 5 655-662.
135. A.H. Moreno, A.I. Katz, L.D. Gold, et al. (1970) Mechanics of distention of dog veins and other thin-walled tubular structures. Circ Res 27 1069-1080.
136. V.B. Nguyen (1976) Sclerotherapie des varices des membres inferieurs: etude de 522 cas. Le Saguency Med 23 134.
137. P. Ouvry and R. Arlaud (1979) Le traitement sclerosant des telangiectasies des membres inferieurs. Phlébologie 32 365-370.
138. P. Ouvry and A. Davy (1982) Le traitement sclerosant des telangiectasies des membres inferieurs. Phlébologie 35 349-359.
139. H. Jager and E. Pelloni (1950) Tests epicutanes aux bichromates, positifs dans l'eczema au ciment. Dermatologica 100 207-216.
140. L. Polak, J.L. Turk and J.R. Frey (1973) Studies on contact hypersensitivity to chromium compounds. Prog Allergy 17 145-226.
141. A.A. Ramelet, C. Ruffieux and D. Poffet (1995) Complications après sclerose à la glycérine chromée. Phlébologie 48 377.
142. P. Albino and J. Monteiro-Castro (2005) Réaction allergique grave après traitement de télangiectasies à la glycérine chrome (Sclérémo®). Phlébologie 58 151-153.
143. P. Wallois (1985) Incidents et accidents de la sclerose. R. Tournay (Eds) La sclerose des varices, 4 edn Paris: Expansion Scientifique Francaise
144. F. Wagener, A. Eggert, O.C. Boerman, et al. (2001) Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 98 1802-1811.
145. I.A. Tabbara (1992) Hemolytic anemias: diagnosis and management. Med Clin North Am 76 649-668.
146. D.A. Clark, S.A. Butler, V. Baren, et al. (1981) The kidneys in paroxysmal nocturnal hemoglobinemia. Blood 57 83-89.
147. R.P. Rother, L. Bell, P. Hillmen, et al. (2005) The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293 1653-1662.
148. H. Dodd (1945) The operation for varicose veins. Br Med J 2 510.
149. E.J. Orbach (1944) Sclerotherapy of varicose veins: utilization of intravenous air block. Am J Surg 66 362.
150. E.J. Orbach (1948) Clinical evaluation of a new technique in the sclerotherapy of varicose veins. J Int Coll Surg 11 396.
151. H.F. Richardson, B.C. Coles and G.E. Hall (1937) Experimental air embolism. Can Med J 36 584.
152. P.T. Hagen, D.G. Schultz and W.D. Edwards (1984) Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 59 17-20.
153. J.J. Lynch, G.H. Schuchard, C.M. Gross, et al. (1984) Prevalence of right to left atrial shunting in a healthy population: detection by valsalva maneuver contrast echocardiography. Am J Cardiol 53 1478-1480.
154. Weiss R, Weiss MA, Wright DDI. Safety of intravenous foam for the treatment of varicose veins. Detection and effects of circulating bubbles following microfoam. Abstract. 18th Annual Congress of the American College of Phlebology. Florida; 2004.
155. D.M. Eckmann, S. Kobayashi and M. Li (2005) Microvascular embolization following polidocanol microfoam sclerosant administration. Dermatol Surg 31 636-643.